



Clinical trial results:

MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2019-004686-41 |
| Trial protocol | GB GR CZ DE ES |
| Global end of trial date | 02 July 2024 |

Results information

| | |
|--------------------------------|--------------|
| Result version number | v1 (current) |
| This version publication date | 16 July 2025 |
| First version publication date | 16 July 2025 |

Trial information

Trial identification

| | |
|-----------------------|---------|
| Sponsor protocol code | IBA1160 |
|-----------------------|---------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04817189 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Helsinn Healthcare SA |
| Sponsor organisation address | Via Pian Scairolo 9, Pazzallo-Lugano, Switzerland, |
| Public contact | HelpDesk, Institut biostatistiky a analýz, s.r.o., +420 515915 100, helpdesk@biostatistika.cz |
| Scientific contact | HelpDesk, Institut biostatistiky a analýz, s.r.o., +420 515915 100, helpdesk@biostatistika.cz |
| Sponsor organisation name | Helsinn Healthcare SA |
| Sponsor organisation address | Via Pian Scairolo 9, Pazzallo-Lugano, Switzerland, |
| Public contact | Alessandro Alonzi - Medical Advisor, Helsinn Healthcare SA, Alessandro.Alonzi@helsinn.com |
| Scientific contact | Alessandro Alonzi - Medical Advisor, Helsinn Healthcare SA, Alessandro.Alonzi@helsinn.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|--------------|
| Analysis stage | Final |
| Date of interim/final analysis | 24 June 2025 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 02 July 2024 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To evaluate if the use of NEPA (netupitant and palonosetron) in patients treated with IV moderately emetogenic chemotherapy and at high risk of CINV is more effective in preventing CINV than standard of care antiemetics over three cycles of chemotherapy

Protection of trial subjects:

The trial subjects were treated according to a common clinical practice. The only intervention in the trial was randomization.

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 01 February 2021 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Spain: 75 |
| Country: Number of subjects enrolled | United Kingdom: 17 |
| Country: Number of subjects enrolled | Czechia: 84 |
| Country: Number of subjects enrolled | Germany: 97 |
| Country: Number of subjects enrolled | Greece: 76 |
| Country: Number of subjects enrolled | China: 53 |
| Country: Number of subjects enrolled | Switzerland: 12 |
| Worldwide total number of subjects | 414 |
| EEA total number of subjects | 332 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |

| | |
|--|-----|
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 223 |
| From 65 to 84 years | 190 |
| 85 years and over | 1 |

Subject disposition

Recruitment

Recruitment details:

Start recruitment date (FPI): 01.02.2021

Stop recruitment date (LPI): 04.04.2024

Territories: Czech Republic, Greece, Germany, Switzerland, United Kingdom, China, Spain

Pre-assignment

Screening details:

Screened patients: 427

Screen failure: 12

Total analysis set: 415

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|------|
| Are arms mutually exclusive? | Yes |
| Arm title | NEPA |

Arm description:

One capsule of NEPA and Dexamethasone 8 mg (or equivalent corticosteroids) by the oral route on Day 1, approximately 1 hour before chemotherapy

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | Akynzeo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Capsule |
| Routes of administration | Oral use |

Dosage and administration details:

One capsule of NEPA by the oral route on Day 1, approximately 1 hour before chemotherapy

| | |
|------------------|------------------|
| Arm title | Standard of care |
|------------------|------------------|

Arm description:

- One of the 5-HT₃-RAs recommended by MASCC/ESMO guidelines (standard of care), i.e. either: Granisetron, 2 mg (oral) or 1 mg (IV)

OR

Palonosetron, 0.5 mg (oral) or 0.25mg (IV)

OR

Ondansetron, 16 mg (oral) or 8 mg (IV)

OR

Dolasetron 100 mg (oral)

OR

Tropisetron 5 mg (oral or IV)

- Dexamethasone (or equivalent corticosteroids) 8 mg administered by the oral route (or equivalent IV dose) on Day 1, approximately 1 hour before chemotherapy

| | |
|----------|-------------------|
| Arm type | Active comparator |
|----------|-------------------|

| | |
|--|-------------------------------|
| Investigational medicinal product name | Granisetron |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Intravesical solution, Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Granisetron, 2 mg (oral) or 1 mg (IV)

| Number of subjects in period 1 | NEPA | Standard of care |
|--|------|------------------|
| Started | 206 | 208 |
| Completed | 171 | 177 |
| Not completed | 35 | 31 |
| Discontinuation of chemotherapy treatment due to C | 2 | 1 |
| Adverse event, serious fatal | 2 | 1 |
| Consent withdrawn by subject | 12 | 3 |
| Adverse event, non-fatal | 2 | 5 |
| General or specific changes in the patient's condi | 6 | 7 |
| Non-qualification to perform consecutive cycles (e | 3 | 10 |
| Lost to follow-up | 5 | 3 |
| Protocol deviation | 3 | 1 |

Baseline characteristics

Reporting groups

| | |
|--------------------------------|---------------|
| Reporting group title | Overall trial |
| Reporting group description: - | |

| Reporting group values | Overall trial | Total | |
|--|---------------|-------|--|
| Number of subjects | 414 | 414 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 223 | 223 | |
| From 65-84 years | 190 | 190 | |
| 85 years and over | 1 | 1 | |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 62.7 | | |
| standard deviation | ± 11.5 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 187 | 187 | |
| Male | 227 | 227 | |

Subject analysis sets

| | |
|----------------------------|-------------------|
| Subject analysis set title | Full Analysis set |
| Subject analysis set type | Full analysis |

Subject analysis set description:

The Full Analysis Set (FAS) consists of 401 (NEPA: 196, SoC: 205) randomised patients to whom study drug was dispensed.

| Reporting group values | Full Analysis set | | |
|--|-------------------|--|--|
| Number of subjects | 401 | | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | | |
| Newborns (0-27 days) | 0 | | |
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 0 | | |

| | | | |
|----------------------|--------|--|--|
| Adults (18-64 years) | 210 | | |
| From 65-84 years | 190 | | |
| 85 years and over | 1 | | |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 62.7 | | |
| standard deviation | ± 11.5 | | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 180 | | |
| Male | 221 | | |

End points

End points reporting groups

| | |
|-----------------------|------|
| Reporting group title | NEPA |
|-----------------------|------|

Reporting group description:

One capsule of NEPA and Dexamethasone 8 mg (or equivalent corticosteroids) by the oral route on Day 1, approximately 1 hour before chemotherapy

| | |
|-----------------------|------------------|
| Reporting group title | Standard of care |
|-----------------------|------------------|

Reporting group description:

- One of the 5-HT3-RAs recommended by MASCC/ESMO guidelines (standard of care), i.e. either:
Granisetron, 2 mg (oral) or 1 mg (IV)
OR
Palonosetron, 0.5 mg (oral) or 0.25mg (IV)
OR
Ondansetron, 16 mg (oral) or 8 mg (IV)
OR
Dolasetron 100 mg (oral)
OR
Tropisetron 5 mg (oral or IV)

- Dexamethasone (or equivalent corticosteroids) 8 mg administered by the oral route (or equivalent IV dose) on Day 1, approximately 1 hour before chemotherapy

| | |
|----------------------------|-------------------|
| Subject analysis set title | Full Analysis set |
|----------------------------|-------------------|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

The Full Analysis Set (FAS) consists of 401 (NEPA: 196, SoC: 205) randomised patients to whom study drug was dispensed.

Primary: The primary endpoint was complete response (defined as no emetic episode(s) and no use of rescue medication), during the overall phase (0-120h), after the start of the MEC administration over three consecutive cycles of chemotherapy.

| | |
|-----------------|---|
| End point title | The primary endpoint was complete response (defined as no emetic episode(s) and no use of rescue medication), during the overall phase (0-120h), after the start of the MEC administration over three consecutive cycles of chemotherapy. |
|-----------------|---|

End point description:

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

End of study

| End point values | NEPA | Standard of care | | |
|-----------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 189 | 199 | | |
| Units: Probability (%) | | | | |
| number (not applicable) | 81.0 | 71.8 | | |

Statistical analyses

| | |
|--|---|
| Statistical analysis title | Probability to experience complete response |
| Statistical analysis description: | |
| Primary endpoint was defined as complete response over three cycles of chemotherapy. To estimate the probability of complete response, a generalized linear model with covariates was used to evaluate the treatment effect of the NEPA compared to the SoC arm. Estimated OR from model was used to derive the difference in the probability of responders between treatment arms. Model-based statistics were used to calculate the difference in the probability to experience a "per cycle" complete response. | |
| Comparison groups | NEPA v Standard of care |
| Number of subjects included in analysis | 388 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.05 |
| Method | a generalized linear model with covariat |

Secondary: Complete response during the acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle

| | |
|---|--|
| End point title | Complete response during the acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle | |

| End point values | NEPA | Standard of care | | |
|-----------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 189 | 199 | | |
| Units: Probability (%) | | | | |
| number (not applicable) | 80.2 | 71.1 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: No emetic episode during the acute, delayed and overall phase and daily in each cycle

| | |
|---|---|
| End point title | No emetic episode during the acute, delayed and overall phase and daily in each cycle |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| the acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle | |

| End point values | NEPA | Standard of care | | |
|-----------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 189 | 199 | | |
| Units: Probability (%) | | | | |
| number (not applicable) | 95.4 | 86.7 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of vomiting episodes during the acute, delayed and overall phase and daily in each cycle

| | |
|------------------------|---|
| End point title | Number of vomiting episodes during the acute, delayed and overall phase and daily in each cycle |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle |

| End point values | NEPA | Standard of care | | |
|--|-----------------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 189 | 199 | | |
| Units: mean difference of episodes per cycle | | | | |
| number (confidence interval 95%) | -0.37 (-0.6 to -0.14) | 0.0 (0.0 to 0.0) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: No rescue medication during the acute, delayed and overall phase and daily in each cycle

| | |
|------------------------|--|
| End point title | No rescue medication during the acute, delayed and overall phase and daily in each cycle |
| End point description: | |
| End point type | Secondary |

End point timeframe:

acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle

| End point values | NEPA | Standard of care | | |
|-----------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 189 | 200 | | |
| Units: Probability (%) | | | | |
| number (not applicable) | 82.4 | 76.5 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: No significant nausea (maximum MAT scale = 2) during the acute, delayed and overall phase and daily in each cycle

| | |
|-----------------|---|
| End point title | No significant nausea (maximum MAT scale = 2) during the acute, delayed and overall phase and daily in each cycle |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle

| End point values | NEPA | Standard of care | | |
|-----------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 188 | 197 | | |
| Units: Probability (%) | | | | |
| number (not applicable) | 77.5 | 72.7 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: No nausea (MAT scale = 0) during the acute, delayed and overall phase and daily in each cycle

| | |
|-----------------|---|
| End point title | No nausea (MAT scale = 0) during the acute, delayed and overall phase and daily in each cycle |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle

| End point values | NEPA | Standard of care | | |
|-----------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 189 | 199 | | |
| Units: Probability (%) | | | | |
| number (not applicable) | 63.7 | 54.9 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Complete protection (no emetic episode, no rescue medication and no significant nausea) during the acute, delayed and overall phase and daily in each cycle

| | |
|-----------------|---|
| End point title | Complete protection (no emetic episode, no rescue medication and no significant nausea) during the acute, delayed and overall phase and daily in each cycle |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

acute (0-24h), delayed phase (>24-120h), overall (0-120h) and daily in each cycle

| End point values | NEPA | Standard of care | | |
|-----------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 188 | 198 | | |
| Units: Probability (%) | | | | |
| number (not applicable) | 71.8 | 62.4 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Nausea and Vomiting-related quality of life indicators (through the Functional Living Index Emesis scale)

| | |
|-----------------|---|
| End point title | Nausea and Vomiting-related quality of life indicators (through the Functional Living Index Emesis scale) |
|-----------------|---|

End point description:

| | |
|-----------------------------------|-----------|
| End point type | Secondary |
| End point timeframe: per cycle | |

| End point values | NEPA | Standard of care | | |
|-------------------------------------|--------------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 189 | 199 | | |
| Units: Mean difference between arms | | | | |
| number (confidence interval 95%) | 3.5 (0.05 to 6.96) | 1.0 (1.0 to 1.0) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Collection of chemotherapy delays (Delay of chemotherapy administration due to CINV were also evaluated as part of health economic endpoints)

| | |
|-----------------|---|
| End point title | Collection of chemotherapy delays (Delay of chemotherapy administration due to CINV were also evaluated as part of health economic endpoints) |
|-----------------|---|

End point description:

| | |
|-----------------------------------|-----------|
| End point type | Secondary |
| End point timeframe: per cycle | |

| End point values | NEPA | Standard of care | | |
|---------------------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 184 | 193 | | |
| Units: mean of delay days per patient | | | | |
| arithmetic mean (standard deviation) | 1.1 (± 3.49) | 1.2 (± 3.45) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Collection of chemotherapy dose reductions

| | |
|------------------------|--|
| End point title | Collection of chemotherapy dose reductions |
| End point description: | |

| | |
|-----------------------------------|-----------|
| End point type | Secondary |
| End point timeframe: per cycle | |

| End point values | NEPA | Standard of care | | |
|-----------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 184 | 193 | | |
| Units: Probability (%) | | | | |
| number (not applicable) | 3.0 | 4.1 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of daily doses of rescue medication administered for the treatment of CINV

| | |
|-----------------|---|
| End point title | Number of daily doses of rescue medication administered for the treatment of CINV |
|-----------------|---|

End point description:

| | |
|-----------------------------------|-----------|
| End point type | Secondary |
| End point timeframe: per cycle | |

| End point values | NEPA | Standard of care | | |
|--------------------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 187 | 200 | | |
| Units: mean dose | | | | |
| arithmetic mean (standard deviation) | 16.3 (± 68.53) | 46.3 (± 343.13) | | |

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of days of rescue medication administered for the treatment of CINV

| | |
|-----------------|--|
| End point title | Number of days of rescue medication administered for the treatment of CINV |
|-----------------|--|

End point description:

| | |
|-----------------------------------|---------------------|
| End point type | Other pre-specified |
| End point timeframe: per cycle | |

| End point values | NEPA | Standard of care | | |
|--------------------------------------|-------------------|-------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 187 | 200 | | |
| Units: mean of days and doses | | | | |
| arithmetic mean (standard deviation) | 0.5 (\pm 1.20) | 0.5 (\pm 1.13) | | |

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of re-hydration bags given for at least grade 2 vomiting (more details below)

| | |
|-----------------|--|
| End point title | Number of re-hydration bags given for at least grade 2 vomiting (more details below) |
|-----------------|--|

End point description:

| | |
|-----------------------------------|---------------------|
| End point type | Other pre-specified |
| End point timeframe: per cycle | |

| End point values | NEPA | Standard of care | | |
|---|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 187 | 198 | | |
| Units: mean number of re-hydration bags per pat | | | | |
| arithmetic mean (standard deviation) | 0.0 (\pm 0) | 0.0 (\pm 0.2) | | |

Statistical analyses

No statistical analyses for this end point

Other pre-specified: The number of days of unplanned hospitalisations related to CINV and department of hospitalization (type of ward)

| | |
|-----------------|---|
| End point title | The number of days of unplanned hospitalisations related to CINV and department of hospitalization (type of ward) |
|-----------------|---|

End point description:

| | |
|-----------------------------------|---------------------|
| End point type | Other pre-specified |
| End point timeframe: per cycle | |

| End point values | NEPA | Standard of care | | |
|--|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 187 | 198 | | |
| Units: Mean number of days per patient | | | | |
| arithmetic mean (standard deviation) | 0.0 (± 0.07) | 0.1 (± 0.75) | | |

Statistical analyses

No statistical analyses for this end point

Other pre-specified: The number of outpatient physician visits and health care consultations due to CINV (e.g., general practitioner)

| | |
|-----------------|--|
| End point title | The number of outpatient physician visits and health care consultations due to CINV (e.g., general practitioner) |
|-----------------|--|

End point description:

| | |
|-----------------------------------|---------------------|
| End point type | Other pre-specified |
| End point timeframe: per cycle | |

| End point values | NEPA | Standard of care | | |
|--------------------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 196 | 205 | | |
| Units: mean of visits per patient | | | | |
| arithmetic mean (standard deviation) | 0.0 (± 0.07) | 0.0 (± 0.16) | | |

Statistical analyses

No statistical analyses for this end point

Other pre-specified: The number of unplanned laboratory tests including those at unplanned hospitalisations due to CINV

| | |
|-----------------|--|
| End point title | The number of unplanned laboratory tests including those at unplanned hospitalisations due to CINV |
|-----------------|--|

End point description:

| | |
|----------------|---------------------|
| End point type | Other pre-specified |
|----------------|---------------------|

End point timeframe:
per cycle

| End point values | NEPA | Standard of care | | |
|--------------------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 187 | 198 | | |
| Units: mean number of tests | | | | |
| arithmetic mean (standard deviation) | 0.0 (± 0.07) | 0.1 (± 0.46) | | |

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Discontinuation of chemotherapy treatment due to CINV

End point title Discontinuation of chemotherapy treatment due to CINV

End point description:

End point type Other pre-specified

End point timeframe:
per cycle

| End point values | NEPA | Standard of care | | |
|-----------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 196 | 205 | | |
| Units: patients | 1 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Delay of chemotherapy administration due to CINV

End point title Delay of chemotherapy administration due to CINV

End point description:

End point type Other pre-specified

End point timeframe:
per cycle

| End point values | NEPA | Standard of care | | |
|--------------------------------------|------------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0 ^[1] | 2 | | |
| Units: mean of days of delay | | | | |
| arithmetic mean (standard deviation) | () | 7 (± 0) | | |

Notes:

[1] - no patients discontinued from CINV

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Days of absence from work

| | |
|-----------------|---------------------------|
| End point title | Days of absence from work |
|-----------------|---------------------------|

End point description:

| | |
|----------------|---------------------|
| End point type | Other pre-specified |
|----------------|---------------------|

End point timeframe:

per cycle

| End point values | NEPA | Standard of care | | |
|--------------------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 5 | 3 | | |
| Units: mean of days of absence | | | | |
| arithmetic mean (standard deviation) | 3 (± 3.08) | 5.7 (± 4.16) | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From a dose of antiemetic drug is administration to the end of the study, the day of Visit 4. Visit 4 is a visit on Day 5 of Cycle 3 or before the start of the next programmed chemotherapy cycle.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|--------------------|--------|
| Dictionary name | MedDRA |
| Dictionary version | 27.1 |

Reporting groups

| | |
|-----------------------|------|
| Reporting group title | NEPA |
|-----------------------|------|

Reporting group description: -

| | |
|-----------------------|------------------|
| Reporting group title | Standard of care |
|-----------------------|------------------|

Reporting group description: -

| Serious adverse events | NEPA | Standard of care | |
|--|-------------------|-------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 22 / 196 (11.22%) | 23 / 205 (11.22%) | |
| number of deaths (all causes) | 2 | 2 | |
| number of deaths resulting from adverse events | | | |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombosis | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Surgical and medical procedures | | | |
| Antibiotic therapy | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Death | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 2 / 196 (1.02%) | 2 / 205 (0.98%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 2 | |
| Pyrexia | | | |
| subjects affected / exposed | 3 / 196 (1.53%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General physical health deterioration | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chills | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pain | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Immune system disorders | | | |
| Drug hypersensitivity | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 2 / 205 (0.98%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cough | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|-----------------|-----------------|--|
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Laryngospasm | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary oedema | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Throat irritation | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Investigations | | | |
| Oxygen saturation decreased | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Platelet count decreased | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Fall | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Cerebrovascular accident | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 2 / 196 (1.02%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aphasia | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral artery occlusion | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hemianopia | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Neutropenia | | | |
| subjects affected / exposed | 6 / 196 (3.06%) | 5 / 205 (2.44%) | |
| occurrences causally related to treatment / all | 0 / 6 | 2 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancytopenia | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Nausea | | | |
| subjects affected / exposed | 2 / 196 (1.02%) | 5 / 205 (2.44%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diarrhoea | | | |
| subjects affected / exposed | 3 / 196 (1.53%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Vomiting | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 196 (0.51%) | 3 / 205 (1.46%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Cholangitis | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholangitis acute | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholestasis | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyper-transaminasaemia | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Renal failure | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue | | | |

| | | | |
|---|-----------------|-----------------|--|
| disorders | | | |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Infection | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 2 / 205 (0.98%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Abscess oral | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| COVID-19 | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Catheter site infection | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Erysipelas | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis salmonella | | | |
| subjects affected / exposed | 1 / 196 (0.51%) | 0 / 205 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|--|-----------------|-----------------|--|
| Lower respiratory tract infection subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ludwig angina subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Septic shock subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders Tumour lysis syndrome subjects affected / exposed | 0 / 196 (0.00%) | 1 / 205 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 2 %

| Non-serious adverse events | NEPA | Standard of care | |
|--|--------------------|--------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 174 / 196 (88.78%) | 183 / 205 (89.27%) | |
| Vascular disorders | | | |
| Peripheral coldness | | | |
| subjects affected / exposed | 5 / 196 (2.55%) | 4 / 205 (1.95%) | |
| occurrences (all) | 7 | 6 | |
| Hypotension | | | |
| subjects affected / exposed | 2 / 196 (1.02%) | 5 / 205 (2.44%) | |
| occurrences (all) | 2 | 5 | |
| Nervous system disorders | | | |

| | | |
|-------------------------------|-------------------|-------------------|
| Paraesthesia | | |
| subjects affected / exposed | 33 / 196 (16.84%) | 26 / 205 (12.68%) |
| occurrences (all) | 49 | 43 |
| Dizziness | | |
| subjects affected / exposed | 24 / 196 (12.24%) | 15 / 205 (7.32%) |
| occurrences (all) | 31 | 16 |
| Neuropathy peripheral | | |
| subjects affected / exposed | 15 / 196 (7.65%) | 20 / 205 (9.76%) |
| occurrences (all) | 24 | 28 |
| Headache | | |
| subjects affected / exposed | 18 / 196 (9.18%) | 15 / 205 (7.32%) |
| occurrences (all) | 25 | 22 |
| Hypoaesthesia | | |
| subjects affected / exposed | 11 / 196 (5.61%) | 20 / 205 (9.76%) |
| occurrences (all) | 14 | 24 |
| Neurotoxicity | | |
| subjects affected / exposed | 10 / 196 (5.10%) | 8 / 205 (3.90%) |
| occurrences (all) | 11 | 8 |
| Dysgeusia | | |
| subjects affected / exposed | 8 / 196 (4.08%) | 7 / 205 (3.41%) |
| occurrences (all) | 8 | 10 |
| Polyneuropathy | | |
| subjects affected / exposed | 6 / 196 (3.06%) | 7 / 205 (3.41%) |
| occurrences (all) | 9 | 7 |
| Somnolence | | |
| subjects affected / exposed | 7 / 196 (3.57%) | 5 / 205 (2.44%) |
| occurrences (all) | 10 | 10 |
| Cold dysaesthesia | | |
| subjects affected / exposed | 4 / 196 (2.04%) | 3 / 205 (1.46%) |
| occurrences (all) | 4 | 4 |
| Peripheral sensory neuropathy | | |
| subjects affected / exposed | 5 / 196 (2.55%) | 2 / 205 (0.98%) |
| occurrences (all) | 8 | 2 |
| Taste disorder | | |
| subjects affected / exposed | 2 / 196 (1.02%) | 4 / 205 (1.95%) |
| occurrences (all) | 2 | 5 |

| | | | | |
|--|---------------------------------------|-------------------|-------------------|--|
| Blood and lymphatic system disorders | Neutropenia | | | |
| | subjects affected / exposed | 8 / 196 (4.08%) | 7 / 205 (3.41%) | |
| | occurrences (all) | 8 | 8 | |
| | Anaemia | | | |
| | subjects affected / exposed | 3 / 196 (1.53%) | 8 / 205 (3.90%) | |
| | occurrences (all) | 3 | 8 | |
| | Leukocytosis | | | |
| | subjects affected / exposed | 1 / 196 (0.51%) | 4 / 205 (1.95%) | |
| | occurrences (all) | 1 | 4 | |
| General disorders and administration site conditions | Fatigue | | | |
| | subjects affected / exposed | 54 / 196 (27.55%) | 46 / 205 (22.44%) | |
| | occurrences (all) | 83 | 78 | |
| | Asthenia | | | |
| | subjects affected / exposed | 25 / 196 (12.76%) | 21 / 205 (10.24%) | |
| | occurrences (all) | 33 | 27 | |
| | General physical health deterioration | | | |
| | subjects affected / exposed | 3 / 196 (1.53%) | 12 / 205 (5.85%) | |
| | occurrences (all) | 3 | 12 | |
| | Pain | | | |
| | subjects affected / exposed | 6 / 196 (3.06%) | 7 / 205 (3.41%) | |
| | occurrences (all) | 9 | 10 | |
| | Pyrexia | | | |
| | subjects affected / exposed | 4 / 196 (2.04%) | 7 / 205 (3.41%) | |
| | occurrences (all) | 4 | 10 | |
| | Oedema peripheral | | | |
| | subjects affected / exposed | 1 / 196 (0.51%) | 8 / 205 (3.90%) | |
| | occurrences (all) | 1 | 8 | |
| | Chest pain | | | |
| | subjects affected / exposed | 2 / 196 (1.02%) | 4 / 205 (1.95%) | |
| | occurrences (all) | 2 | 4 | |
| | Chills | | | |
| | subjects affected / exposed | 1 / 196 (0.51%) | 4 / 205 (1.95%) | |
| | occurrences (all) | 1 | 4 | |
| Ear and labyrinth disorders | | | | |

| | | | |
|--|-------------------------|-------------------------|--|
| Vertigo subjects affected / exposed occurrences (all) | 4 / 196 (2.04%) 4 | 7 / 205 (3.41%) 7 | |
| Gastrointestinal disorders | | | |
| Diarrhoea subjects affected / exposed occurrences (all) | 40 / 196 (20.41%) 63 | 48 / 205 (23.41%) 66 | |
| Constipation subjects affected / exposed occurrences (all) | 41 / 196 (20.92%) 52 | 29 / 205 (14.15%) 42 | |
| Abdominal pain subjects affected / exposed occurrences (all) | 19 / 196 (9.69%) 26 | 25 / 205 (12.20%) 31 | |
| Nausea subjects affected / exposed occurrences (all) | 15 / 196 (7.65%) 22 | 17 / 205 (8.29%) 32 | |
| Dyspepsia subjects affected / exposed occurrences (all) | 9 / 196 (4.59%) 12 | 6 / 205 (2.93%) 10 | |
| Dry mouth subjects affected / exposed occurrences (all) | 8 / 196 (4.08%) 10 | 6 / 205 (2.93%) 8 | |
| Abdominal discomfort subjects affected / exposed occurrences (all) | 3 / 196 (1.53%) 4 | 10 / 205 (4.88%) 11 | |
| Abdominal pain upper subjects affected / exposed occurrences (all) | 6 / 196 (3.06%) 6 | 2 / 205 (0.98%) 2 | |
| Stomatitis subjects affected / exposed occurrences (all) | 4 / 196 (2.04%) 5 | 4 / 205 (1.95%) 4 | |
| Dysphagia subjects affected / exposed occurrences (all) | 1 / 196 (0.51%) 3 | 6 / 205 (2.93%) 9 | |
| Eructation | | | |

| | | | |
|---|------------------|-----------------|--|
| subjects affected / exposed | 5 / 196 (2.55%) | 2 / 205 (0.98%) | |
| occurrences (all) | 6 | 2 | |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 5 / 196 (2.55%) | 1 / 205 (0.49%) | |
| occurrences (all) | 5 | 1 | |
| Hypoaesthesia oral | | | |
| subjects affected / exposed | 2 / 196 (1.02%) | 4 / 205 (1.95%) | |
| occurrences (all) | 2 | 5 | |
| Vomiting | | | |
| subjects affected / exposed | 2 / 196 (1.02%) | 4 / 205 (1.95%) | |
| occurrences (all) | 2 | 5 | |
| Abdominal distension | | | |
| subjects affected / exposed | 4 / 196 (2.04%) | 1 / 205 (0.49%) | |
| occurrences (all) | 4 | 2 | |
| Flatulence | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 4 / 205 (1.95%) | |
| occurrences (all) | 0 | 7 | |
| Oral pain | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 4 / 205 (1.95%) | |
| occurrences (all) | 0 | 4 | |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 196 (0.00%) | 4 / 205 (1.95%) | |
| occurrences (all) | 0 | 5 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Hiccups | | | |
| subjects affected / exposed | 10 / 196 (5.10%) | 4 / 205 (1.95%) | |
| occurrences (all) | 11 | 5 | |
| Epistaxis | | | |
| subjects affected / exposed | 5 / 196 (2.55%) | 8 / 205 (3.90%) | |
| occurrences (all) | 5 | 10 | |
| Dyspnoea | | | |
| subjects affected / exposed | 4 / 196 (2.04%) | 6 / 205 (2.93%) | |
| occurrences (all) | 4 | 7 | |
| Cough | | | |

| | | | |
|--|------------------------|------------------------|--|
| subjects affected / exposed occurrences (all) | 5 / 196 (2.55%) 5 | 1 / 205 (0.49%) 1 | |
| Oropharyngeal pain subjects affected / exposed occurrences (all) | 5 / 196 (2.55%) 5 | 1 / 205 (0.49%) 1 | |
| Throat irritation subjects affected / exposed occurrences (all) | 1 / 196 (0.51%) 2 | 4 / 205 (1.95%) 7 | |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia subjects affected / exposed occurrences (all) | 9 / 196 (4.59%) 10 | 12 / 205 (5.85%) 15 | |
| Erythema subjects affected / exposed occurrences (all) | 5 / 196 (2.55%) 5 | 7 / 205 (3.41%) 13 | |
| Rash subjects affected / exposed occurrences (all) | 9 / 196 (4.59%) 10 | 2 / 205 (0.98%) 2 | |
| Pruritus subjects affected / exposed occurrences (all) | 3 / 196 (1.53%) 3 | 5 / 205 (2.44%) 6 | |
| Dry skin subjects affected / exposed occurrences (all) | 1 / 196 (0.51%) 1 | 5 / 205 (2.44%) 6 | |
| Psychiatric disorders | | | |
| Insomnia subjects affected / exposed occurrences (all) | 4 / 196 (2.04%) 5 | 8 / 205 (3.90%) 10 | |
| Restlessness subjects affected / exposed occurrences (all) | 2 / 196 (1.02%) 2 | 4 / 205 (1.95%) 6 | |
| Musculoskeletal and connective tissue disorders | | | |
| Pain in extremity subjects affected / exposed occurrences (all) | 11 / 196 (5.61%) 13 | 16 / 205 (7.80%) 26 | |
| Arthralgia | | | |

| | | | |
|------------------------------------|-------------------|-------------------|--|
| subjects affected / exposed | 6 / 196 (3.06%) | 7 / 205 (3.41%) | |
| occurrences (all) | 6 | 7 | |
| Muscle spasms | | | |
| subjects affected / exposed | 4 / 196 (2.04%) | 7 / 205 (3.41%) | |
| occurrences (all) | 6 | 12 | |
| Bone pain | | | |
| subjects affected / exposed | 7 / 196 (3.57%) | 3 / 205 (1.46%) | |
| occurrences (all) | 7 | 3 | |
| Limb discomfort | | | |
| subjects affected / exposed | 6 / 196 (3.06%) | 2 / 205 (0.98%) | |
| occurrences (all) | 7 | 2 | |
| Back pain | | | |
| subjects affected / exposed | 3 / 196 (1.53%) | 4 / 205 (1.95%) | |
| occurrences (all) | 3 | 7 | |
| Muscular weakness | | | |
| subjects affected / exposed | 4 / 196 (2.04%) | 2 / 205 (0.98%) | |
| occurrences (all) | 4 | 2 | |
| Myalgia | | | |
| subjects affected / exposed | 2 / 196 (1.02%) | 4 / 205 (1.95%) | |
| occurrences (all) | 3 | 6 | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 23 / 196 (11.73%) | 30 / 205 (14.63%) | |
| occurrences (all) | 33 | 47 | |
| Hypokalaemia | | | |
| subjects affected / exposed | 5 / 196 (2.55%) | 3 / 205 (1.46%) | |
| occurrences (all) | 5 | 3 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported